NCT01969682

A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199

A Phase 1 Study to Assess the Effect of Rifampin on the Pharmacokinetics of ABT-199

• Status: Withdrawn
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: AbbVie · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label multicenter, study to assess the pharmacokinetic interaction of rifampin with ABT-199 in up to 12 subjects with relapsed or refractory non-Hodgkin's lymphoma.

Detailed description

This is a Phase 1 study designed to assess how the body processes the study drug ABT-199 when taken alone and in combination with rifampin and to assess the safety of ABT-199 in combination with rifampin. Subjects may enroll in a separate extension study to continue receiving ABT-199 after completion of this study.

Conditions

• Non-Hodgkin's Lymphoma

Interventions

Type	Name	Description
DRUG	ABT-199	Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with rifampin
DRUG	Rifampin	Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with rifampin

Timeline

• Start date: 2014-04-01
• Primary completion: 2014-05-01
• Completion: 2014-05-01
• First posted: 2013-10-25
• Last updated: 2014-05-26

Locations

1 site across 1 country: United States